Patents by Inventor Bolyn Hubby
Bolyn Hubby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10570416Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: GrantFiled: August 11, 2016Date of Patent: February 25, 2020Assignee: ALPHAVAX, INC.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Publication number: 20180318218Abstract: Nanolipoprotein particles comprising at least a scaffold protein component and a membrane lipid component and related complexes, compositions, methods and systems are described, in which the membrane lipid component comprises at least one or more membrane forming lipids and one or more cationic lipids.Type: ApplicationFiled: May 2, 2018Publication date: November 8, 2018Inventors: Kurt I. Kamrud, Nathaniel S. Wang, Martina Felderman, Bolyn Hubby, Heather D. Gouvis, Nicholas O. Fischer, Matthew A. Coleman, Angela Clare Evans, Wei He, Amy Rasley, Craig D. Blanchette
-
Patent number: 10111943Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: GrantFiled: June 29, 2016Date of Patent: October 30, 2018Assignee: ALPHAVAX, INC.Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
-
Publication number: 20160375124Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: ApplicationFiled: June 29, 2016Publication date: December 29, 2016Inventors: Jonathan F. SMITH, Bolyn Hubby, Laura Copp
-
Publication number: 20160348132Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: August 11, 2016Publication date: December 1, 2016Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
-
Patent number: 9441247Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: GrantFiled: July 6, 2015Date of Patent: September 13, 2016Assignee: ALPHAVAX, INC.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Patent number: 9416370Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: GrantFiled: October 18, 2010Date of Patent: August 16, 2016Assignee: AlphaVax, Inc.Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
-
Publication number: 20150299728Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: July 6, 2015Publication date: October 22, 2015Inventors: Jon O. RAYNER, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Publication number: 20150273079Abstract: A method of stimulating an immune response in a subject including administering a micrometer-sized particle coupled with an antigen to the subject, wherein increasing the aspect ratio of the micrometer-sized particle increases the immune response. A method of stimulating an immune response in a subject including administering to the subject a plurality of particles, wherein each particle is coupled with an immuno stimulating agent and a protein. A vaccine particle composition including a plurality of particles configured to release a first protein at a first rate and a second protein at a second rate and configured to provide priming and boosting capability in a single dose.Type: ApplicationFiled: June 11, 2015Publication date: October 1, 2015Applicant: Liquidia Technologies, Inc.Inventors: Bolyn Hubby, Andrew Murphy, Jeff Kindig, Jesse White, Samantha Roth, Ashley L. Galloway, Laura Copp
-
Patent number: 9079943Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: GrantFiled: March 28, 2014Date of Patent: July 14, 2015Assignee: ALPHAVAX, INC.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Publication number: 20140205629Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: March 28, 2014Publication date: July 24, 2014Applicant: AlphaVax, Inc.Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
-
Patent number: 8709441Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: GrantFiled: July 6, 2010Date of Patent: April 29, 2014Assignee: Alphavax, Inc.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Publication number: 20130209564Abstract: Particle compositions are prepared for use as polysaccharide particle vaccines.Type: ApplicationFiled: February 22, 2011Publication date: August 15, 2013Inventors: Shyam M. Rele, Andrew Murphy, Bolyn Hubby
-
Patent number: 8263092Abstract: The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: GrantFiled: September 12, 2007Date of Patent: September 11, 2012Assignee: AlphaVax, Inc.Inventors: Jonathan F. Smith, Bolyn Hubby, Peter Berglund, Laura Copp, Whitney Ellis
-
Publication number: 20120213813Abstract: The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: ApplicationFiled: September 12, 2007Publication date: August 23, 2012Applicant: AlphaVax, Inc.Inventors: Jonathan F. Smith, Bolyn Hubby, Peter Berglund, Laura Copp, Whitney Ellis
-
Publication number: 20110151015Abstract: A method of stimulating an immune response in a subject including administering a micrometer-sized particle coupled with an antigen to the subject, wherein increasing the aspect ratio of the micrometer-sized particle increases the immune response. A method of stimulating an immune response in a subject including administering to the subject a plurality of particles, wherein each particle is coupled with an immuno stimulating agent and a protein. A vaccine particle composition including a plurality of particles configured to release a first protein at a first rate and a second protein at a second rate and configured to provide priming and boosting capability in a single dose.Type: ApplicationFiled: March 4, 2009Publication date: June 23, 2011Applicant: LIQUIKIA TECHNOLOGIES, INC.Inventors: Bolyn Hubby, Andrew Murphy, Jeff Kindig, Jesse White, Samantha Roth, Ashley L. Galloway, Laura Copp
-
Publication number: 20110086062Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: ApplicationFiled: October 18, 2010Publication date: April 14, 2011Applicant: AlphaVax, Inc.Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
-
Publication number: 20110027306Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: July 6, 2010Publication date: February 3, 2011Applicant: AlphaVax, Inc.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Publication number: 20090022760Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: ApplicationFiled: September 12, 2007Publication date: January 22, 2009Applicant: AlphaVaxInventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
-
Publication number: 20050266550Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: May 18, 2005Publication date: December 1, 2005Applicant: Alphavax, Inc.Inventors: Jon Rayner, Jonathan Smith, Bolyn Hubby, Elizabeth Reap